A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Terminated
35 enrolled
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
Phase 1 Terminated
99 enrolled
MAST
Phase 1 Terminated
66 enrolled
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
21 enrolled
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Phase 1 Terminated
42 enrolled
PRIMING
Phase 1 Terminated
2 enrolled 10 charts
Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
Phase 1 Terminated
3 enrolled
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Terminated
79 enrolled 24 charts
POP-ART
Phase 1 Terminated
10 enrolled
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Phase 1 Terminated
122 enrolled
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
Phase 1 Terminated
36 enrolled 7 charts
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Phase 1 Terminated
105 enrolled
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
23 enrolled
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1 Terminated
77 enrolled
A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Phase 1 Terminated
33 enrolled
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Phase 1 Terminated
88 enrolled
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
Phase 1 Terminated
3 enrolled
Panthera
Phase 1 Terminated
2 enrolled
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
Phase 1 Terminated
3 enrolled 9 charts
A Study to Investigate LYL797 in Adults With Solid Tumors
Phase 1 Terminated
57 enrolled
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Terminated
9 enrolled
PROBE
Phase 1 Terminated
31 enrolled
RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
Phase 1 Terminated
15 enrolled
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
Phase 1 Terminated
6 enrolled
ICVB-1042
Phase 1 Terminated
17 enrolled
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
Phase 1 Terminated
272 enrolled
Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
Phase 1 Terminated
34 enrolled
Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
Phase 1 Terminated
38 enrolled
QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
Phase 1 Terminated
3 enrolled 10 charts
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors
Phase 1 Terminated
192 enrolled
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
Phase 1 Terminated
7 enrolled
First in Human Study of M1069 in Advanced Solid Tumors
Phase 1 Terminated
15 enrolled
V938-001
Phase 1 Terminated
35 enrolled 21 charts
LTbR
Phase 1 Terminated
4 enrolled
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Terminated
22 enrolled 21 charts
Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
Phase 1 Terminated
74 enrolled
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
Phase 1 Terminated
10 enrolled
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
37 enrolled 32 charts
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
49 enrolled 33 charts
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors
Phase 1 Terminated
12 enrolled
Study of GNX102 in Patients With Advanced Solid Tumors
Phase 1 Terminated
46 enrolled
Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
Phase 1 Terminated
32 enrolled 19 charts
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases
Phase 1 Terminated
7 enrolled
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Phase 1 Terminated
14 enrolled 20 charts
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL
Phase 1 Terminated
3 enrolled
A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
Phase 1 Terminated
11 enrolled
Safety Study of SEA-CD40 in Cancer Patients
Phase 1 Terminated
159 enrolled